Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2019
Reporting Period: The filing primarily addresses corporate actions effective July 9, 2019, and references preliminary financial results for the second quarter of fiscal year 2019.
Key Financial Metrics
This Form 8-K does not contain specific numerical financial data (revenue, profit, cash flow, margins, debt, or liquidity). It references a press release (Exhibit 99.1) containing preliminary second-quarter fiscal year 2019 results, but the specific figures are not included in the text of this filing.
Material Changes
- Reverse Stock Split: The Company's Board of Directors authorized a 1-for-9 reverse stock split of its common stock.
- Effective Date: The split became effective at 5:30 p.m. ET on July 9, 2019.
- Corporate Governance: An amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on July 8, 2019, to effectuate the split.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release on July 9, 2019, disclosing preliminary Q2 2019 financial results and announcing the reverse stock split. No specific forward-looking guidance or risk factors are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the specific preliminary Q2 2019 financial results in the press release (Exhibit 99.1) referenced in Item 2.02.
- Confirm the post-split share count and adjusted share price following the 1-for-9 reverse split effective July 9, 2019.
- Review the amended Certificate of Incorporation (Exhibit 3.1) for details on authorized share capital changes.